However, a complete cure for NASH with only a single target is unrealistic, and the limitation of this paper is also in the fact that deubiquitinating enzymes that act directly on the UPS degradation of CYP2E1 have not been identified, and other studies have not been reported. The gene discussed is CYP2E1; the disease is metabolic dysfunction-associated steatohepatitis.